Primary goal achieved in Mirum’s Phase IIb trial of volixibat

Mirum Pharmaceuticals has reported that its VISTAS Phase IIb clinical study of volixibat has achieved its primary goal in patients with PSC. Top line data from the VANTAGE study of volixibat in primary biliary cholangitis are expected in the first quarter of 2027. PSC is a rare, long-term disease marked by inflammation, scarring, and narrowing of bile ducts inside and outside the liver. Credit: Yuriy K / Shutterstock.com. Mirum Pharmaceuticals has reported that its VISTAS Phase IIb clinical study of volixibat, an investigational oral ileal bile acid transporter inhibitor, has achieved its primary goal in patients with primary sclerosing cholangitis…

Source: Clinical Trials Arena